Annual report pursuant to Section 13 and 15(d)

Correction of Previously Issued Financial Statements

v3.23.1
Correction of Previously Issued Financial Statements
12 Months Ended
Dec. 31, 2022
Accounting Changes and Error Corrections [Abstract]  
Correction of Previously Issued Financial Statements

Note 2 – Correction of Previously Issued Financial Statements

 

In the course of preparing its fiscal year 2022 financial statements, the Company identified errors in the financial statements for the year ended December 31, 2021 and its unaudited financial statements for the periods ended March 31, 2022, June 30, 2022, and September 30, 2022. The errors pertain to understatements in research and development expenses and accrued expenses amounting to $458,622 for the year ended December 31, 2021 and $367,439 for the three months ended March 31, 2022, the six months ended June 30, 2022 and the nine months ended September 30, 2022 resulting from additional trial sites costs which were not reported to the Company by our CRO.

 

The Company assessed the materiality of these misstatements on prior periods’ financial statements in accordance with SEC Staff Accounting Bulletin (“SAB”) No. 99, Materiality, codified in ASC 250 (“ASC 250”), Presentation of Financial Statements, and concluded that these misstatements were not material to any prior annual or interim periods. Accordingly, in accordance with ASC 250 (SAB No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements), the Financial Statements as of December 31, 2021, and the year then ended, which are presented herein, have been revised. The following are selected line items from the Company's balance sheets, statements of operations and statements of cash flows for the affected periods illustrating the effect of these corrections:

 

     
Balance Sheet   As of December 31,
2021
 
    As Reported     Adjustment     As Revised  
                   
Accounts payable   $ 1,522,823     $ 458,622     $ 1,981,445  
Total current liabilities     2,135,566       458,622       2,594,188  
Total liabilities     2,135,566       458,622       2,594,188  
                         
Accumulated deficit     (34,982,921 )     (458,622 )     (35,441,543 )
Total stockholders' equity     6,621,819       (458,622 )     6,163,197  

 

       
Balance Sheet
(Unaudited)
  As of March 31,
2022
 
    As Reported     Adjustment     As Revised  
                   
Accounts payable   $ 489,716     $ 826,061     $ 1,315,777  
Total current liabilities     1,069,300       826,061       1,895,361  
Total liabilities     1,069,300       826,061       1,895,361  
                         
Accumulated deficit     (37,767,260 )     (826,061 )     (38,593,321 )
Total stockholders' equity     14,802,567       (826,061 )     13,976,506  

 

       
Balance Sheet
(Unaudited)
  As of June 30,
2022
 
    As Reported     Adjustment     As Revised  
                   
Accounts payable   $ 490,886     $ 826,061     $ 1,316,947  
Total current liabilities     923,856       826,061       1,749,917  
Total liabilities     923,856       826,061       1,749,917  
                         
Accumulated deficit     (41,333,212 )     (826,061 )     (42,159,273 )
Total stockholders' equity     11,523,456       (826,061 )     10,697,395  

 

       
Balance Sheet
(Unaudited)
  As of September 30,
2022
 
    As Reported     Adjustment     As Revised  
                   
Accounts payable   $ 1,005,043     $ 826,061     $ 1,831,104  
Total current liabilities     1,244,303       826,061       2,070,364  
Total liabilities     1,244,303       826,061       2,070,364  
                         
Accumulated deficit     (44,752,765 )     (826,061 )     (45,578,826 )
Total stockholders' equity     8,393,624       (826,061 )     7,567,563  

 

       
Statement of Operations   For the year ended December 31,
2021
 
    As Reported     Adjustment     As Revised  
                   
Research and development   $ 9,346,453     $ 458,622     $ 9,805,075  
Total operating expenses     14,027,293       458,622       14,485,915  
Loss from operations     (14,027,293 )     (458,622 )     (14,485,915 )
Net loss     (14,036,578 )     (458,622 )     (14,495,200 )
Loss per share - basic and diluted     (15.98 )     (0.52 )     (16.50 )

 

       
Statement of Operations
(Unaudited)
  For the three months ended March 31,
2022
 
    As Reported     Adjustment     As Revised  
                   
Research and development   $ 1,521,364     $ 367,439     $ 1,888,803  
Total operating expenses     2,781,773       367,439       3,149,212  
Loss from operations     (2,781,773 )     (367,439 )     (3,149,212 )
Net loss     (2,784,339 )     (367,439 )     (3,151,778 )
Loss per share - basic and diluted     (2.15 )     (0.28 )     (2.44 )

 

Statement of Operations
(Unaudited)
  For the six months ended June 30,
2022
 
    As Reported     Adjustment     As Revised  
                   
Research and development   $ 3,742,703     $ 367,439     $ 4,110,142  
Total operating expenses     6,346,114       367,439       6,713,553  
Loss from operations     (6,346,114 )     (367,439 )     (6,713,553 )
Net loss     (6,350,291 )     (367,439 )     (6,717,730 )
Loss per share - basic and diluted     (4.83 )     (0.28 )     (5.11 )

 

Statement of Operations
(Unaudited)
  For the nine months ended September 30,
2022
 
    As Reported     Adjustment     As Revised  
                   
Research and development   $ 5,950,616     $ 367,439     $ 6,318,055  
Total operating expenses     9,765,129       367,439       10,132,568  
Loss from operations     (9,765,129 )     (367,439 )     (10,132,568 )
Net loss     (9,769,844 )     (367,439 )     (10,137,283 )
Loss per share - basic and diluted     (7.40 )     (0.27 )     (7.67 )

 

       
Statement of Cash Flows   For the year ended December 31,
2021
 
    As Reported     Adjustment     As Revised  
                   
Cash Flows from Operating Activities:                        
Net loss   $ (14,036,578 )   $ (458,622 )   $ (14,495,200 )
Accounts payable     576,493       458,622       1,035,115  
Net cash used in operating activities     (13,538,309 )           (13,538,309 )

 

       
Statement of Cash Flows
(Unaudited)
  For the three months ended March 31,
2022
 
    As Reported     Adjustment     As Revised  
                   
Cash Flows from Operating Activities:                        
Net loss   $ (2,784,339 )   $ (367,439 )   $ (3,151,778 )
Accounts payable     (1,033,107 )     367,439       (665,668 )
Net cash used in operating activities     (3,077,199 )           (3,077,199 )

 

       
Statement of Cash Flows
(Unaudited)
  For the six months ended June 30,
2022
 
    As Reported     Adjustment     As Revised  
                   
Cash Flows from Operating Activities:                        
Net loss   $ (6,350,291 )   $ (367,439 )   $ (6,717,730 )
Accounts payable     (1,031,937 )     367,439       (664,498 )
Net cash used in operating activities     (6,439,733 )           (6,439,733 )

 

       
Statement of Cash Flows
(Unaudited)
  For the nine months ended September 30,
2022
 
    As Reported     Adjustment     As Revised  
                   
Cash Flows from Operating Activities:                        
Net loss   $ (9,769,844 )   $ (367,439 )   $ (10,137,283 )
Accounts payable     (517,780 )     367,439       (150,341 )
Net cash used in operating activities     (8,252,492 )           (8,252,492 )